Business Wire

CMG-DIGITAL

25.4.2022 01:02:06 CEST | Business Wire | Press release

Share
CMG Digital Relaunches With a New Vision to Put the Humanity Back Into Digital

Global digital design and smart production agency CMG Digital is today relaunching as part of an ongoing evolution of its company brand.

The agency, based in Croatia, with a presence in the UK and the US, now has a new vision and is dedicating itself to putting humanity back into digital.

The acceleration of digital adoption during the pandemic brought many positives to the digital space, including investment, faster development, new services and virtual worlds. At the same time, it has also tackled issues around security, privacy, sustainability and inefficiencies.

More significantly, the acceleration of digital has seen a move towards automation and away from humanisation in digital.

The relaunched CMG Digital is the answer: an agency dedicated to supporting clients to ensure they can maximise success in digital within this context.

The new vision will also be accompanied by a new look. With the agency debuting a new logo, theme and tone of voice. The updated visual identity will represent the evolved brand values.

Putting humanity at the core of its company was an easy decision for the agency, which boasts two thirds of women holding the top management positions as well as women making up more than 55% of the overall employees. CMG Digital also boasts a mental health program called MindGiving to support the team: this includes yoga classes, managing stress workshops, meeting limits, no meeting Friday as well as additional health insurance.

Explaining the new vision, Ana Tolić, President of CMG said:

“We are both delighted and excited to enter this new era of CMG Digital history and focus on our mission of putting humanity back into digital.

“Over the course of the pandemic the lightning-fast adoption of digital meant the space quickly became inhuman and cold.

“We are an agency that recognises that we can’t replace the people's side of things with a platform, and that relationships are critical to success. We believe in focusing on B2H – Business to Human.”

The relaunch will also keep digital sustainability at the heart of the agency.

CMG Digital is known for setting the industry tone when it comes to sustainability. Historically, the agency standardised recycling long before it became compulsory. Now, it is leading the way once more and focussing on standardising its approach to digital sustainability.

As global-to-local experts, CMG Digital puts a strong focus on maximising content life through reuse, recycling and repurposing to reduce the digital waste of its clients.

This focus is allowing CMG Digital to spread its message, educate and upskilling clients and brands in digital sustainability as well as digital inclusivity.

CMG Digital hopes that its position as a leader in its field will enable it to set the tone and encourage other agencies to follow its example. The agency is a powerhouse in its industry, credited with delivering over 50,000 projects, working with more than 200 global brands and delivering to over 100 markets worldwide. Since 2001 it has been the digital custodian of some of the world’s most valuable brands across the globe, and today leading digital deployment for multinational corporations such as P&G, GSK, Novartis, ConvaTec, Cloetta, Edgewell and Rimac.

CMG Digital believes its relaunch will help it better achieve its overall goal of empowering brands to scale their global message to the local level with consistency and pace.

-ENDS-

Link:

ClickThru

Social Media:

https://www.facebook.com/CMGCroatia/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye